Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment Source: Eur Respir J 2003; 22: 251-257 Year: 2003
Metabolic disturbances in patients with obstructive sleep apnoea syndrome Source: Eur Respir Rev 2007; 16: 196-202 Year: 2007
The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Comparisson of corrective effects of APAP and CPAP on disordered autonomic nervous system function in patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2007; 30: Suppl. 51, 332s Year: 2007
Determinant factors of serum leptin levels in patients with obstructive sleep apnea Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005
The state and responsiveness of the renin-angiotensin-aldosterone system in obstructive sleep apnoea Source: Eur Respir J 2003; 22: Suppl. 45, 90s Year: 2003
Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients Source: Eur Respir J 2004; 23: 255-262 Year: 2004
Associations between increased serum leptin levels and the severity of obstructive sleep apnoea independent of obesity Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009
Impact of CPAP treatment on sympathetic activity and renin-angiotensin-aldosterone system in normotensive men with obstructive sleep apnoea Source: Eur Respir J 2006; 28: Suppl. 50, 294s Year: 2006
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
Serum leptin levels in obstructive sleep apnoea patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Cardiovascular and metabolic effects of CPAP in obese males with OSA Source: Eur Respir J 2007; 29: 720-727 Year: 2007
Impact of obstructive sleep apnoea (OSA) on glucose metabolism Source: Annual Congress 2007 - Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment Year: 2007
Impact of continuous positive airways pressure treatment on autonomic nervous system activity in patients with sleep apnoea Source: Eur Respir J 2002; 20: Suppl. 38, 294s Year: 2002
Effect of 8 week CPAP therapy on insulin resistance, serum leptin and lipid concentrations among obstructive sleep apnea hypopnea syndrome (OSAS) patients Source: Eur Respir J 2004; 24: Suppl. 48, 330s Year: 2004
Relationship between obstructive sleep apnea syndrome (OSAS) and obesity, cholesterol disorders, blood pressure, and anatomical alterations Source: Eur Respir J 2006; 28: Suppl. 50, 817s Year: 2006
Serum leptin levels in obese patients with severe obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
Elevated leptin is associated with impaired glucose tolerance in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 573s Year: 2006
The impact of serum leptin and soluble leptin receptor (sOB-R) levels on respiratory chemosensitivities in obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2006; 28: Suppl. 50, 413s Year: 2006
Metabolic consequences in obstructive sleep apnoea Source: Annual Congress 2006 - PG9 - Obstructive sleep apnoea: current pathophysiological, clinical and therapeutic concepts Year: 2006